AstraZeneca and Absci’s Collaboration May Lead to AI-Generated Cancer Antibodies as Potential Alternative to Chemotherapy
AstraZeneca and Absci have reportedly signed a lucrative deal valued at around $247 million to develop cancer antibodies…
AstraZeneca and Absci have reportedly signed a lucrative deal valued at around $247 million to develop cancer antibodies…